Orthocell Secures Singapore Regulatory Approval for Striate+

Orthocell Ltd ( (AU:OCC) ) just unveiled an update.

Orthocell Limited has received regulatory approval from Singapore’s Health Sciences Authority for its dental membrane product, Striate+, marking a significant milestone in its global expansion strategy. This approval not only validates the quality of Orthocell’s products but also positions the company to capitalize on Singapore as a strategic hub for further ASEAN market penetration. With a strong balance sheet and robust sales growth driven by positive clinical feedback, Orthocell is well-positioned to increase its market share in the AU$1 billion global market opportunity, targeting a 20% share.

More about Orthocell Ltd

Orthocell Limited is a regenerative medicine company specializing in dental and tissue regeneration products. Its primary product, Striate+, is a sterile, resorbable collagen membrane used in dental bone and tissue regeneration applications, including dental implant procedures. The company focuses on expanding its market presence globally, with existing approvals in the US, Europe/UK, Australia, New Zealand, and Canada.

YTD Price Performance: -8.82%

Average Trading Volume: 1,603,785

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$300M

See more data about OCC stock on TipRanks’ Stock Analysis page.